

gabriele Buda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4904521/publications.pdf>

Version: 2024-02-01

115
papers

1,477
citations

393982

19
h-index

377514

34
g-index

118
all docs

118
docs citations

118
times ranked

2743
citing authors

#	ARTICLE	IF	CITATIONS
1	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	1.4	5
2	Daratumumab in AL Amyloidosis: A Real-Life Experience of the "Regional Tuscan Myeloma" (RTM) (Regional Tuscan Myeloma) Tj ETQq0 0 Q rgBT /Overlock 10 T	1.1	2
3	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. <i>Hematology Reports</i> , 2022, 14, 19-23.	0.3	1
4	Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retrospective observational study. <i>European Journal of Haematology</i> , 2022, 109, 373-380.	1.1	6
5	[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 246-255.	2.3	51
6	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 41-50.	0.8	22
7	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. <i>JACC: Case Reports</i> , 2021, 3, 450-454.	0.3	2
8	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3
9	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
10	Mesangiogenic Progenitor Cells Are Tissue Specific and Cannot Be Isolated From Adipose Tissue or Umbilical Cord Blood. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669381.	1.8	2
11	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 900.	0.8	2
12	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 712070.	1.2	4
13	Piezoelectric Signals in Vascularized Bone Regeneration. <i>Biomolecules</i> , 2021, 11, 1731.	1.8	18
14	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1806-1815.	0.8	60
15	Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 155-176.	2.1	34
16	Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 138-144.	1.1	5
17	The CoV-2 outbreak: how hematologists could help to fight Covid-19. <i>Pharmacological Research</i> , 2020, 157, 104866.	3.1	36
18	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. <i>Frontiers in Immunology</i> , 2020, 11, 573156.	2.2	8

#	ARTICLE	IF	CITATIONS
19	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 532.	1.3	14
20	Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia. <i>TH Open</i> , 2019, 03, e64-e66.	0.7	8
21	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2019, 19, 83.	1.8	3
22	Different types of amyloid concomitantly present in the same patients. <i>Hematology Reports</i> , 2019, 11, 7996.	0.3	3
23	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019, 141, 7-11.	0.7	0
24	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
25	Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. <i>Oncotarget</i> , 2019, 10, 6781-6790.	0.8	2
26	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ na ⁺ ve lymphocytes and prevents TTV reactivation. <i>Leukemia Research</i> , 2018, 70, 20-24.	0.4	36
27	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 555.	1.3	18
28	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	1.2	11
29	Cardiac light-chain deposition disease relapsing in the transplanted heart. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 135-137.	1.4	4
30	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
31	PRDI-BF1 and PRDI-BF1 ² isoform expressions correlate with disease status in multiple myeloma patients. <i>Hematology Reports</i> , 2017, 9, 7201.	0.3	2
32	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
33	How to facilitate early diagnosis of CNS involvement in malignant lymphoma. <i>Expert Review of Hematology</i> , 2016, 9, 1081-1091.	1.0	10
34	CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance. <i>Acta Haematologica</i> , 2016, 135, 11-14.	0.7	11
35	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5697-5697.	0.6	2
36	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ Naïve and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. <i>Blood</i> , 2016, 128, 1230-1230.	0.6	0
38	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
39	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38
40	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	1.6	11
41	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	2.3	30
42	CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD. <i>Blood</i> , 2015, 126, 1768-1768.	0.6	0
43	Myelomatous Meningitis Evaluated by Multiparameter Flow Cytometry : Report of a Case and Review of the Literature. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2014, 54, 129-136.	0.3	18
44	Primary non-Hodgkin lymphoma in the pterygopalatine fossa. A peculiar diagnosis with a minimally invasive endoscopic approach. <i>Annals of Hematology</i> , 2014, 93, 345-346.	0.8	1
45	Genetic Variants and Multiple Myeloma Risk: IMMENSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	1.1	13
46	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e13-e17.	0.2	3
47	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMENSE consortium. <i>Journal of Human Genetics</i> , 2013, 58, 155-159.	1.1	5
48	Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2013, 129, 35-39.	0.7	7
49	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. <i>Hematological Oncology</i> , 2013, 31, 72-78.	0.8	11
50	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4383-4383.	0.6	1
51	VDTPACEAs Salvage Therapy For Heavily Pretreated MM Patients. <i>Blood</i> , 2013, 122, 5377-5377.	0.6	11
52	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659.	0.6	0
53	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809.	1.2	19
54	Could age modify the effect of genetic variants in IL6 and TNF- β genes in multiple myeloma?. <i>Leukemia Research</i> , 2012, 36, 594-597.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMESE consortium. <i>British Journal of Haematology</i> , 2012, 157, 331-338.	1.2	13
56	Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2012, 120, 1645-1645.	0.6	1
57	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. <i>Blood</i> , 2012, 120, 2929-2929.	0.6	0
58	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMESE consortium (Review). <i>International Journal of Oncology</i> , 2011, 40, 625-38.	1.4	14
59	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Supportive Care in Cancer</i> , 2011, 19, 1505-1510.	1.0	20
60	Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. <i>Annals of Hematology</i> , 2011, 90, 1115-1116.	0.8	3
61	Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. <i>Leukemia Research</i> , 2011, 35, 899-903.	0.4	20
62	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1942-1948.	0.6	28
63	Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2011, 118, 4585-4585.	0.6	3
64	Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMESE Consortium. <i>Blood</i> , 2011, 118, 5014-5014.	0.6	0
65	Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. <i>Annals of Hematology</i> , 2010, 89, 1133-1140.	0.8	54
66	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. <i>Leukemia Research</i> , 2010, 34, 184-189.	0.4	28
67	Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. <i>Leukemia Research</i> , 2010, 34, 1336-1339.	0.4	17
68	Fludarabine, Bortezomib, Myocet [®] and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 810-812.	1.2	12
69	correspondence: CD23 expression in plasma cell leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 724-725.	1.2	4
70	Age-Dependent Influence of TNF- α Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1829-1829.	0.6	0
71	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. <i>Blood</i> , 2010, 116, 5033-5033.	0.6	0
72	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. <i>Acta Haematologica</i> , 2009, 122, 39-41.	0.7	2

#	ARTICLE	IF	CITATIONS
73	MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. Acta Haematologica, 2009, 122, 42-45.	0.7	10
74	Aggressive Non Hodgkin lymphoma' patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis.. Blood, 2009, 114, 4772-4772.	0.6	0
75	Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.. Blood, 2009, 114, 3945-3945.	0.6	0
76	The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.. Blood, 2009, 114, 5007-5007.	0.6	4
77	Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin.. Blood, 2009, 114, 109-109.	0.6	7
78	Incidence of Febrile Episodes During Stem Cells Mobilization After High Dose Cyclophosphamide Chemotherapy and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma Patients: Preliminary Final Results.. Blood, 2009, 114, 4560-4560.	0.6	0
79	Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.. Blood, 2009, 114, 1723-1723.	0.6	0
80	Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression. Medical Science Monitor, 2009, 15, CS27-29.	0.5	5
81	MDR1 modulates apoptosis in CD34+ leukemic cells. Annals of Hematology, 2008, 87, 1017-1018.	0.8	4
82	Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. Journal of Orthopaedic Research, 2008, 26, 176-183.	1.2	34
83	Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. Leukemia Research, 2008, 32, 188-190.	0.4	1
84	Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. Leukemia Research, 2008, 32, 190-191.	0.4	6
85	Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. Leukemia Research, 2008, 32, 192-194.	0.4	4
86	Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. Leukemia Research, 2008, 32, 191-192.	0.4	9
87	Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. Leukemia Research, 2008, 32, 194-195.	0.4	5
88	Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leukemia Research, 2008, 32, 49-53.	0.4	8
89	CD45 expression in low-grade B-cell non-Hodgkin's lymphomas. Leukemia Research, 2008, 32, 263-267.	0.4	24
90	MDR1 pump: More than a drug transporter. Leukemia Research, 2008, 32, 359-360.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. <i>Leukemia Research</i> , 2008, 32, 988-990.	0.4	15
92	Unusual association of endometrial cancer and multiple myeloma. <i>Gynecologic Oncology</i> , 2008, 110, 265-266.	0.6	7
93	Other mechanisms to explain the role of reduced folate carrier in cancer. <i>European Journal of Haematology</i> , 2008, 80, 365-365.	1.1	0
94	Folic acid fortification and cancer risk. <i>Lancet, The</i> , 2008, 371, 1336.	6.3	0
95	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	1.7	92
96	MDR1 diplotypes as prognostic markers in multiple myeloma. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 383-389.	0.7	30
97	TNF- α Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib. <i>Blood</i> , 2008, 112, 216-216.	0.6	1
98	Incidence of Febrile Episode During Stem Cell Mobilization (SCM) After High Dose Cyclophosphamide Chemotherapy (HD-CTX) and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma (MM) Patients: II Interim Evaluation. <i>Blood</i> , 2008, 112, 4135-4135.	0.6	0
99	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. <i>Acta Haematologica</i> , 2007, 118, 27-29.	0.7	7
100	Folate levels and methylation of CDKI proteins. <i>Leukemia Research</i> , 2007, 31, 569-570.	0.4	4
101	A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13). <i>Leukemia Research</i> , 2007, 31, 1599-1600.	0.4	1
102	Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). <i>Leukemia Research</i> , 2007, 31, 1765-1766.	0.4	9
103	NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. <i>Leukemia Research</i> , 2007, 31, 1029-1030.	0.4	10
104	Association of PIM gene translocation and TEL/AML1 rearrangement. <i>Leukemia Research</i> , 2007, 31, 1761-1762.	0.4	1
105	MDR1 polymorphism influences the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2007, 137, 454-456.	1.2	45
106	Unexpected cardiotoxicity in haematological bortezomib treated patients. <i>British Journal of Haematology</i> , 2007, 138, 396-397.	1.2	181
107	Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 166-167.	1.0	1
108	Folate levels in cancer: a vitamin for a new challenge. <i>Annals of Hematology</i> , 2007, 86, 389-389.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Stable low IgG levels in relapsed non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2007, 86, 851-853.	0.8	1
110	Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin's Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen.. <i>Blood</i> , 2007, 110, 4498-4498.	0.6	1
111	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 3468-3468.	0.6	0
112	Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. <i>Melanoma Research</i> , 2006, 16, 467-468.	0.6	4
113	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. <i>Blood</i> , 2005, 106, 4670-4670.	0.6	0
114	Unusual concomitant small- and large-fiber neuropathy related to hypereosinophilic syndrome. <i>Clinical and Experimental Neuroimmunology</i> , 0, , .	0.5	0
115	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	1.1	2